Abstract
The clinical application of acute drug testing for the treatment of ventricular arrhythmias is limited by epidemiologic, statistical and therapeutic uncertainties. The suppression of ventricular premature complexes (VPCs) is confounded by statistical analyses that require high-grade suppression simply to confirm a true response1,2 and by the lack of clinical evidence of efficacy with respect to mortality.3 Repetitive forms of VPCs are generally considered more important than single VPCs,4 and improved clinical outcome has been associated with the high-grade suppression of repetitive forms in selected high-risk subgroups.5 However, the spontaneous variability of repetitive forms is frequently even more marked than single VPCs, rendering statistical analysis nearly impossible.6 Although these uncertainties have directed attention to the suppression of sustained and nonsustained ventricular tachycardia, both in drug development and therapies, there remains a clinical need to test acutely the efficacy of antiarrhythmic drugs against manifest ventricular arrhythmias. We report a new approach to this evaluation.
| Original language | English |
|---|---|
| Pages (from-to) | 648-650 |
| Number of pages | 3 |
| Journal | The American journal of cardiology |
| Volume | 67 |
| Issue number | 7 |
| DOIs | |
| State | Published - Mar 15 1991 |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Indexing repetitive to single ventricular premature complexes : A new concept in acute drug testing. / Kessler, Kenneth M.; Castellanos, Agustin; Myerburg, Robert J.
In: The American journal of cardiology, Vol. 67, No. 7, 15.03.1991, p. 648-650.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Indexing repetitive to single ventricular premature complexes
T2 - A new concept in acute drug testing
AU - Kessler, Kenneth M.
AU - Castellanos, Agustin
AU - Myerburg, Robert J
PY - 1991/3/15
Y1 - 1991/3/15
N2 - The clinical application of acute drug testing for the treatment of ventricular arrhythmias is limited by epidemiologic, statistical and therapeutic uncertainties. The suppression of ventricular premature complexes (VPCs) is confounded by statistical analyses that require high-grade suppression simply to confirm a true response1,2 and by the lack of clinical evidence of efficacy with respect to mortality.3 Repetitive forms of VPCs are generally considered more important than single VPCs,4 and improved clinical outcome has been associated with the high-grade suppression of repetitive forms in selected high-risk subgroups.5 However, the spontaneous variability of repetitive forms is frequently even more marked than single VPCs, rendering statistical analysis nearly impossible.6 Although these uncertainties have directed attention to the suppression of sustained and nonsustained ventricular tachycardia, both in drug development and therapies, there remains a clinical need to test acutely the efficacy of antiarrhythmic drugs against manifest ventricular arrhythmias. We report a new approach to this evaluation.
AB - The clinical application of acute drug testing for the treatment of ventricular arrhythmias is limited by epidemiologic, statistical and therapeutic uncertainties. The suppression of ventricular premature complexes (VPCs) is confounded by statistical analyses that require high-grade suppression simply to confirm a true response1,2 and by the lack of clinical evidence of efficacy with respect to mortality.3 Repetitive forms of VPCs are generally considered more important than single VPCs,4 and improved clinical outcome has been associated with the high-grade suppression of repetitive forms in selected high-risk subgroups.5 However, the spontaneous variability of repetitive forms is frequently even more marked than single VPCs, rendering statistical analysis nearly impossible.6 Although these uncertainties have directed attention to the suppression of sustained and nonsustained ventricular tachycardia, both in drug development and therapies, there remains a clinical need to test acutely the efficacy of antiarrhythmic drugs against manifest ventricular arrhythmias. We report a new approach to this evaluation.
UR - http://www.scopus.com/inward/record.url?scp=0025971355&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025971355&partnerID=8YFLogxK
U2 - 10.1016/0002-9149(91)90909-5
DO - 10.1016/0002-9149(91)90909-5
M3 - Article
VL - 67
SP - 648
EP - 650
JO - American Journal of Cardiology
JF - American Journal of Cardiology
SN - 0002-9149
IS - 7
ER -